title: Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection.
abstract: Human respiratory syncytial virus (HRSV) is the most frequent cause of severe respiratory infections in infancy. No vaccine against this virus has yet been protective, and antiviral drugs have been of limited utility. Using the cotton rat model of HRSV infection, we examined bovine respiratory syncytial virus (BRSV), a cause of acute respiratory disease in young cattle, as a possible vaccine candidate to protect children against HRSV infection. Cotton rats were primed intranasally with graded doses of BRSV/375 or HRSV/Long or were left unprimed. Three weeks later, they were challenged intranasally with either BRSV/375, HRSV/Long (subgroup A), or HRSV/18537 (subgroup B). At intervals postchallenge, animals were sacrificed for virus titration and histologic evaluation. Serum neutralizing antibody titers were determined at the time of viral challenge. BRSV/375 replicated to low titers in nasal tissues and lungs. Priming with 10(5) PFU of BRSV/375 effected a 500- to 1,000-fold reduction in peak nasal HRSV titer and a greater than 1,000-fold reduction in peak pulmonary HRSV titer upon challenge with HRSV/Long or HRSV/18537. In contrast to priming with HRSV, priming with BRSV did not induce substantial levels of neutralizing antibody against HRSV and was associated with a delayed onset of clearance of HRSV upon challenge. Priming with BRSV/375 caused mild nasal and pulmonary pathology and did not cause exacerbation of disease upon challenge with HRSV/Long. Our findings suggest that BRSV may be a potential vaccine against HRSV and a useful tool for studying the mechanisms of immunity to HRSV.
authors.affiliation: Children's National Medical Center, Washington, D.C.
authors.forename: F M
authors.initials: FM
authors.lastname: Piazza
authors.forename: S A
authors.initials: SA
authors.lastname: Johnson
authors.forename: M E
authors.initials: ME
authors.lastname: Darnell
authors.forename: D D
authors.initials: DD
authors.lastname: Porter
authors.forename: V G
authors.initials: VG
authors.lastname: Hemming
authors.forename: G A
authors.initials: GA
authors.lastname: Prince
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D003429:Cross Reactions; D005069:Evaluation Studies as Topic; D007110:Immunity, Active; D016233:Immunotherapy, Active; D012136:Respiratory Syncytial Viruses / Q000145:classification / Q000254:growth & development / Q000276:immunology*; D010253:Respirovirus Infections / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D016205:Sigmodontinae; D013045:Species Specificity; D014765:Viral Vaccines / Q000276:immunology*; D014779:Virus Replication
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D014765:Viral Vaccines